839 patients enrolled since the opening of the biobank in September 2013!
SPECTAcolor is the first ever tumour tissue samples biobank and biomarker analysis platform for genetic profiling of patients suffering from advanced colorectal cancer.
This platform, Nike Air Max 2016 Dames Zwart unique of its kind joins up research clinical forces at a Pan-European level to develop personalized treatments based on the results of the tissue sampling analysis.
Supported by a network of over 30 clinical centres in 11 countries, nike air max 2016 grijs nike chaussures this initiative has the ultimate goal of enabling better access to new treatment options. Cheap Fjallraven Kanken Outlet adidas superstar Between 600 and 1000 patients with advanced colorectal cancer are expected to enroll each year.
The SPECTAcolor platform will test molecular alterations in colorectal cancer patients whose disease is spreading fast. Nike air max 90 pas cher Fjallraven Kanken Big These patients are then tested to identify their specific cancer markers to offer the possibility to enter them into biomarker -led clinical trials .
Adult patients with pathologically confirmed metastatic colorectal cancer are invited to give their informed consent to test for mutations in colorectal cancer biomarkers. chaussures nike tn requin new balance femme blanche 996 In addition, Nike Air Max 2016 Heren blauw Nike Pas Cher further other specific cancer genes will be tested using most advanced genetic research technologies to identify deeper alterations that may intrinsically drive cancer cells.